Clinical Trials Logo

Pigmentation Disorders clinical trials

View clinical trials related to Pigmentation Disorders.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06091215 Active, not recruiting - Pigment Skin Clinical Trials

Combining Broad Based Light (BBL), Fractionated 1927 (MOXI) and Dual Wavelength 2940/1470 (HALO)

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a single-site, non-randomized, non-controlled study at UT Southwestern Medical Center at Dallas in the Department of Plastic Surgery. The study is designed to follow up to 15 consenting subjects who may receive up to 2 BBL/MOXI/HALO treatments under an IRB approved protocol.

NCT ID: NCT05913102 Active, not recruiting - Pigmentation Clinical Trials

A Prospective, Split-face, Randomized Study of the Poly-D, L Lactic Acid (PDLLA) for Photoaged Skin

Start date: September 28, 2022
Phase: N/A
Study type: Interventional

Juvelook® (VAIM, Korea) is made by dissolving irregular PDLLA particles in a solvent mixture of DMSO (Dimethylsulfoxide) and EC (Ethylene Carbonate) and then injecting them through microneedling to create reticulated foamy microspheres, which are hollow spherical particles. It received CE approval in Europe in 2020 and is widely used domestically as a material for tissue restoration, including skin fillers and collagen stimulators. The spherical shape with internal foam structure of PDLLA exhibits excellent biocompatibility, biodegradability, porosity, and mechanical strength. It allows for the control of particle size and acts as a collagen stimulator while gradually dissolving over time. This stimulates fibroblast cells and promotes skin rejuvenation. In clinical practice, Juvelook® particles are injected to address various concerns such as facial wrinkles, increased elasticity, depressed scars, acne scars, accident scars, under-eye hollows, freckles, whitening effects, and neck wrinkles. Therefore, this study aims to investigate the efficacy of Juvelook® not only in volume augmentation but also in improving photoaged skin.

NCT ID: NCT04971200 Active, not recruiting - Vitiligo Clinical Trials

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

TILDVIT-1227
Start date: September 16, 2021
Phase: Early Phase 1
Study type: Interventional

Vitiligo is a common acquired depigmentation disorder affecting approximately 2% of the world population. The purpose of this pilot study is to evaluate the effect and the safety of Tildrakizumab in adult participants with vitiligo.